CLAIM CARD
The next high-yield study for Hormone optimization should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.
Evidence grade: exploratory
Contradiction status: none
Publication: 5f852f5b-8941-49c3-950b-b6eed340ec3e
Provenance: Derivation Web chain
Citation Support
source_1Saleh 2023source_2Gu 2024source_3Abdalla 2026source_4Villa 2024source_5Segerer 2020